APR 29, 2015 10:53 PM PDT

New Tack for Treating Alzheimer's Halts Beta Amyloid Production

WRITTEN BY: Judy O'Rourke
Researchers pursuing a fresh approach for staving off Alzheimer's disease may have hit on something.

They have found compounds that block the production of beta amyloid peptides in mice, which could provide an early intervention for Alzheimer's disease (AD).

The compound showing the greatest promise thus far-a peptide called P8-could be given to people found to be at high risk for the disease before symptoms are manifest, if the results bear out for human treatment.

"Our approach is completely different from any current approaches that target beta amyloid," says lead author Nazneen Dewji, PhD, associate adjunct professor, University of California, San Diego School of Medicine. "We are blocking the actual production of beta amyloid in a new way. It's very promising because it means that, in principle, we can stop the disease in its tracks."

The UCSD researchers worked alongside colleagues from biopharma company Cenna Biosciences, Inc, La Jolla, Calif, which Dewji and co-author S. Jonathan Singer, PhD, professor emeritus, Division of Biological Sciences, founded in 2006. Dewji serves as the company's president and CEO.

Accumulation of amyloid plaque is generally thought to cause permanent brain damage. Patients may have a range cognitive and motor damage chiefly connected with AD, which accounts for some 60 to 80 percent of all cases of dementia in the United States.

Due to beta amyloid's implication in the progression of the disease, a number of investigational drugs zero in on enzymes that cleave beta amyloid from its larger precursor protein-amyloid precursor protein (APP).

"These drugs, however, have largely failed in clinical trials, mostly because they are responsible for cleaving other proteins besides APP," Dewji says. "Inhibiting or modifying their activities creates many undesirable effects in the cell."

The P8 compound binds to APP and in the process, thwarts the larger protein from being processed into smaller amyloid peptides.

"Our approach is different, specific, and interferes with only the reaction that produces beta amyloid, as opposed to drugs that target the enzymes responsible for its cleavage from APP, which can affect multiple reactions in cells," Dewji says. Cenna is developing potential drug candidates.

The researchers also performed experiments with young mice designed to generate large amounts of the human beta amyloid. They found that a two-week course of treatment with P8 or a different compound called P4 culminated in, on average, a decline of more than 50 percent in plaque accumulation, versus mice who had no treatment.

"We now have a new approach for the treatment of Alzheimer's disease that can arrest the production of beta amyloid very early and specifically," Dewji says. "It's a real chance at a successful treatment for Alzheimer's disease."

The study, in an article titled "Peptides of Presenilin-1 Bind the Amyloid Precursor Protein Ectodomain and Offer a Novel and Specific Therapeutic Approach to Reduce ß-Amyloid in Alzheimer's Disease," is reported in PLOS ONE.

[Source: UCSD]
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
NOV 03, 2021
Genetics & Genomics
Gene Therapy Could Make Parkinson's Drug More Effective
NOV 03, 2021
Gene Therapy Could Make Parkinson's Drug More Effective
In Parkinson's disease, neurons that produce the neurotransmitter dopamine in a part of the brain called the substantial ...
NOV 04, 2021
Cannabis Sciences
Can Cannabidiol Be Used to Treat a Wide Variety of Seizure Disorders?
NOV 04, 2021
Can Cannabidiol Be Used to Treat a Wide Variety of Seizure Disorders?
In 2015, it was estimated that nearly half a million children had active epilepsy, otherwise known as a seizure disorder ...
NOV 15, 2021
Health & Medicine
Alpha-synuclein as a Biomarker for Parkinson's Disease
NOV 15, 2021
Alpha-synuclein as a Biomarker for Parkinson's Disease
Parkinson’s disease (PD) is a widespread neurogenerative disorder that can significantly impact a person’s q ...
DEC 10, 2021
Neuroscience
Cannabis Use Linked to Poor Sleep Quality
DEC 10, 2021
Cannabis Use Linked to Poor Sleep Quality
Recent cannabis use is linked to either less than 6 hours- short sleep- or more than 9 hours of sleep- long sleep. The s ...
JAN 14, 2022
Technology
Do People Trust Artificial Intelligence?
JAN 14, 2022
Do People Trust Artificial Intelligence?
What exactly is artificial intelligence (AI)?  It may sound like science fiction, and often conjures up images of m ...
JAN 25, 2022
Genetics & Genomics
Genetic Causes of Cerebral Palsy are Discovered
JAN 25, 2022
Genetic Causes of Cerebral Palsy are Discovered
Cerebral palsy (CP) starts in early childhood, and is a motor impairment that does not progress. CP is caused when child ...
Loading Comments...